McKesson reported a strong Q1 with revenue and EPS beats, driven by momentum in North American pharma and oncology. Management raised full-year EPS guidance, citing confidence in underlying fundamentals and strong exit rates, while noting some Q1 timing benefits and planned H2 investments. Total revenue $105.4B (+8%), adj EPS $9.93 (+20%), both beat expectations.
Buzzberg readFiscal 2027 EPS guidance raised to $44.20-$45McKesson reported a strong Q1 with revenue and EPS beats, driven by momentum in North American pharma and oncology. Management raised full-year EPS guidance, citing confidence in underlying fundamentals and strong exit rates, while noting some Q1 timing benefits and planned H2 investments. Total revenue $105.4B (+8%), adj EPS $9.93 (+20%), both beat expectations.Read full analysisCollapse analysis
McKesson reported a strong Q1 with revenue and EPS beats, driven by momentum in North American pharma and oncology. Management raised full-year EPS guidance, citing confidence in underlying fundamentals and strong exit rates, while noting some Q1 timing benefits and planned H2 investments. Total revenue $105.4B (+8%), adj EPS $9.93 (+20%), both beat expectations.
NAP operating profit growth raised to high end of 5.5-9.5% range, driven by specialty distribution and new launches.
AI, capex & demand read
AI
Platform & monetization
Management highlighted internal AI adoption, including a full-day enterprise AI training and using AI to accelerate software development, reducing a task from months to a single day, but gave no specifics on AI products or monetization.
Demand
Bookings & conversion
Demand signals are strong, with broad-based growth across segments, higher prescription volumes, continued GLP-1 growth, and growth in specialty distribution and access solutions, underpinned by stable utilization trends.
Capex
Investment and capacity
Capital expenditures are directed toward distribution network and technology infrastructure, including a new regional distribution center in Oklahoma that will increase throughput by 75%, with continued investment in distribution, technology, and operational capabilities.
Tone · Confident
Management expressed confidence in the business momentum, raised full-year guidance, and highlighted broad-based strength across the enterprise.
Supply-chain alpha
A1
McKesson's Q1 results benefited from timing advantages in new product launches and brand-to-generic conversions, which will not repeat in later quarters.
“We probably had some benefit from timing in the quarter. Some of that obviously relates to new product launches.”
June was the strongest month of the quarter for McKesson, indicating accelerating momentum as the quarter closed and carrying into Q2.
“We feel really good about the momentum we're seeing in the business and the strength of execution in our Q1 results and the X rate as well. June was the strongest month of the quarter.”
McKesson will accelerate investments in the NAP segment and AI in H2 to drive growth, the ROI of which is expected to materialize starting in fiscal 2028.
“It also incorporates accelerated investments in the business the second half of the year as well, focused on growth and also AI... the return timing will most likely be the beginning of 2028.”
Apollo is providing capital (13% stake) and operational expertise for the MedSurg/Wellverse separation, de-risking the spin and providing liquidity for McKesson's buyback.
“we completed the previously announced strategic minority investment from Apollo Funds, bringing on an important partner with financial resources and experience in complex separations.”
… chain capabilities. This investment strengthens the foundation of our supply chain and positions us to serve our customers with greater scale, resilience, and accuracy. Now let me provide a brief update on our portfolio actions. During the quarter, we continued to successfully execute on the planned separation of medical surgical solutions, allowing us to continue to build momentum towards becoming a standalone company. We completed the previously announced strategic minority investment from Apollo Funds, bringing on an important partner with financial resources and experience in complex separations. Additionally, we completed a $2.25 billion senior secured term loan B, further establishing a standalone capital structure for the business with a clear focus on maximizing long-term value for shareholders. Today, I'm pleased to share that McKesson Medical Surgical Business is becoming Wellverse. Wellverse delivers a future where healthcare providers and patients thrive. This is an important step as we establish a distinct market identity and brand that reflects the organization's purpose and vision. The MedSurg business anticipates formally operating as Wellverse starting in …
This collaboration with McKesson's SCRI JV will streamline trial operations and potentially accelerate Pfizer's oncology pipeline, deepening their partnership.
“Recently SCRI announced a strategic oncology research collaboration with Pfizer to help accelerate clinical trials.”
… additional opportunities to build off distribution and GPO services. It allows us to expand patient participation in clinical trials, generating more data and more insights. Our clinical trial services joint venture, Sarah Cannon Research Institute, continues to bring innovative therapies to patients faster and closer to where they live. SCRI participated in research that contributed to 43 of the 52 adult oncology drugs approved by the FDA in 2025. Recently SCRI announced a strategic oncology research collaboration with Pfizer to help accelerate clinical trials. Through this collaboration SCRI and Pfizer will leverage a next generation clinical trial delivery model designed to streamline trial operations, enhance site efficiency, and reduce administrative burden for investigators and care teams alike. Let's move on to our biopharma services platform. We continue to enable connectivity across providers, biopharma, pharmacies and payers. We're advancing programs that improve access and affordability while allowing patients greater ease and confidence in navigating their prescription journey. In July, we began supporting the CMS Medicare GLP-1 Bridge Program where our integrated …
McKesson's GLP-1 distribution volumes indicate strong market growth in this key category, in which Cencora also competes for share.
“Revenues from GLP-1 medications distribution were $15 billion in the quarter, an increase of approximately $3 billion, or 24%, versus the prior year.”
… contracts are structured such that we are compensated for the fair value of the service we deliver. We continue to play a critical role in the pharmaceutical supply chain with strong value proposition to our manufacturer partners. Leveraging our extensive capabilities, we deliver value beyond distribution including inventory management, central fill, and other services that support customers across the pharmaceutical supply chain. Revenues from GLP-1 medications distribution were $15 billion in the quarter, an increase of approximately $3 billion, or 24%, versus the prior year. Sequentially, GLP-1 revenues increased 13%. Segment operating profit increased 19% to $894 million, driven by growth in specialty distribution, including health systems and strategic accounts, and the timing of new product launches. Fundamentals in the business remain strong, supported by stable utilization trends, specialty growth, and the strength of our generic sourcing program. Our skilled distribution capabilities include McKesson, Plasma, and Biologics position us well to support growth and specialty distribution volumes. Clear as one, our generic sourcing program continues to deliver meaningful …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.